195 related articles for article (PubMed ID: 17511816)
21. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
22. Paradoxical effect to caspofungin in Candida species does not confer survival advantage in a Drosophila model of candidiasis.
Zanette RA; Kontoyiannis DP
Virulence; 2013 Aug; 4(6):497-8. PubMed ID: 23863608
[No Abstract] [Full Text] [Related]
23. Development of New Strategies for Echinocandins: Progress in Translational Research.
Walsh TJ; Azie N; Andes DR
Clin Infect Dis; 2015 Dec; 61 Suppl 6():S601-3. PubMed ID: 26567276
[TBL] [Abstract][Full Text] [Related]
24. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
25. Caspofungin for the treatment of less common forms of invasive candidiasis.
Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin.
Olver WJ; Scott F; Shankland GS
Med Mycol; 2006 Nov; 44(7):655-7. PubMed ID: 17071561
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
[TBL] [Abstract][Full Text] [Related]
28. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature.
Pelletier R; Alarie I; Lagacé R; Walsh TJ
Med Mycol; 2005 Sep; 43(6):559-64. PubMed ID: 16320498
[TBL] [Abstract][Full Text] [Related]
29. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine.
Dumaine V; Eyrolle L; Baixench MT; Paugam A; Larousserie F; Padoin C; Tod M; Salmon D
Int J Antimicrob Agents; 2008 Apr; 31(4):398-9. PubMed ID: 18242959
[No Abstract] [Full Text] [Related]
30. Infections caused by Candida krusei in five transplant and two surgical patients.
Bonatti H; Stelzmueller I; Berger N; Lechner M; Grif K; Geltner C; Margreiter R; Lass-Flörl C
Surg Infect (Larchmt); 2009 Jun; 10(3):265-71. PubMed ID: 19485782
[TBL] [Abstract][Full Text] [Related]
31. Emergence of Candida tropicalis resistant to caspofungin.
Pasquale T; Tomada JR; Ghannoun M; Dipersio J; Bonilla H
J Antimicrob Chemother; 2008 Jan; 61(1):219. PubMed ID: 18024953
[No Abstract] [Full Text] [Related]
32. Three cases of Candida fermentati fungemia following hematopoietic stem cell transplantation.
Morita K; Honda A; Koya J; Toyama K; Ikeda M; Misawa Y; Okugawa S; Nakamura F; Moriya K; Kurokawa M
J Infect Chemother; 2018 Jul; 24(7):576-578. PubMed ID: 29371065
[TBL] [Abstract][Full Text] [Related]
33. Points of concern related to the micafungin versus caspofungin trial.
Eiland EH; Hassoun A; English T
Clin Infect Dis; 2008 Feb; 46(4):640-1; author reply 641. PubMed ID: 18205538
[No Abstract] [Full Text] [Related]
34. Breakthrough Candida dubliniensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin.
Fanci R
J Chemother; 2009 Feb; 21(1):105-7. PubMed ID: 19297283
[No Abstract] [Full Text] [Related]
35. Update on antifungal treatment of invasive Candida and Aspergillus infections.
Maschmeyer G; Ruhnke M
Mycoses; 2004 Aug; 47(7):263-76. PubMed ID: 15310328
[TBL] [Abstract][Full Text] [Related]
36. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
[TBL] [Abstract][Full Text] [Related]
37. Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.
Blanchard E; Lortholary O; Boukris-Sitbon K; Desnos-Ollivier M; Dromer F; Guillemot D;
Antimicrob Agents Chemother; 2011 Nov; 55(11):5358-61. PubMed ID: 21859944
[TBL] [Abstract][Full Text] [Related]
38. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
[TBL] [Abstract][Full Text] [Related]
39. [Impact of antifungal prophylaxis on the gastrointestinal yeast colonisation in patients with haematological malignancies].
Rimek D; Redetzke K; Kappe R
Mycoses; 2006; 49 Suppl 2():18-23. PubMed ID: 17022757
[TBL] [Abstract][Full Text] [Related]
40. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
